NL7312270A - - Google Patents

Info

Publication number
NL7312270A
NL7312270A NL7312270A NL7312270A NL7312270A NL 7312270 A NL7312270 A NL 7312270A NL 7312270 A NL7312270 A NL 7312270A NL 7312270 A NL7312270 A NL 7312270A NL 7312270 A NL7312270 A NL 7312270A
Authority
NL
Netherlands
Application number
NL7312270A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7312270A publication Critical patent/NL7312270A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL7312270A 1972-09-08 1973-09-06 NL7312270A (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US287423A US3862190A (en) 1972-09-08 1972-09-08 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines

Publications (1)

Publication Number Publication Date
NL7312270A true NL7312270A (en:Method) 1974-03-12

Family

ID=23102839

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7312270A NL7312270A (en:Method) 1972-09-08 1973-09-06

Country Status (13)

Country Link
US (1) US3862190A (en:Method)
JP (1) JPS5543463B2 (en:Method)
AR (1) AR202106A1 (en:Method)
AU (1) AU471279B2 (en:Method)
BE (1) BE804414A (en:Method)
CA (1) CA996116A (en:Method)
CH (1) CH581121A5 (en:Method)
DE (1) DE2344611A1 (en:Method)
ES (1) ES418567A1 (en:Method)
FI (1) FI59796C (en:Method)
FR (1) FR2198753B1 (en:Method)
GB (1) GB1434805A (en:Method)
NL (1) NL7312270A (en:Method)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941889A (en) * 1972-09-08 1976-03-02 Pfizer Inc. 5-(Substituted phenoxy)-4-amino pyrimidines as anti-ulcer agents
JPS57164686U (en:Method) * 1981-04-11 1982-10-16
JPS6197973U (en:Method) * 1984-12-03 1986-06-23
JPS63135868U (en:Method) * 1987-02-26 1988-09-06
WO1998014430A1 (fr) * 1996-10-02 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyrimidine
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE60142236D1 (de) * 2000-07-24 2010-07-08 Krenitsky Pharmaceuticals Inc Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
US8895574B2 (en) 2010-12-24 2014-11-25 Nihon Nohyaku Co., Ltd. Benzyloxypyrimidine derivative, agricultural/ horticultural insecticide comprising derivative and method for using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB886693A (en) * 1959-03-04 1962-01-10 Ici Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
FI59796B (fi) 1981-06-30
JPS5543463B2 (en:Method) 1980-11-06
DE2344611A1 (de) 1974-03-14
AU6003173A (en) 1975-03-06
JPS4992080A (en:Method) 1974-09-03
CH581121A5 (en:Method) 1976-10-29
ES418567A1 (es) 1976-08-01
FI59796C (fi) 1981-10-12
AU471279B2 (en) 1976-04-15
FR2198753B1 (en:Method) 1976-09-03
FR2198753A1 (en:Method) 1974-04-05
BE804414A (fr) 1974-03-04
GB1434805A (en) 1976-05-05
CA996116A (en) 1976-08-31
AR202106A1 (es) 1975-05-15
US3862190A (en) 1975-01-21

Similar Documents

Publication Publication Date Title
JPS48103611A (en:Method)
FR2198753B1 (en:Method)
JPS537918B2 (en:Method)
JPS4882204A (en:Method)
FR2169378A1 (en:Method)
JPS5230463Y2 (en:Method)
JPS5311281Y2 (en:Method)
JPS4893097U (en:Method)
JPS4884409U (en:Method)
CS153291B1 (en:Method)
CH570569A5 (en:Method)
CH571907A5 (en:Method)
CH567660A5 (en:Method)
CH545876A (en:Method)
CH569186A5 (en:Method)
CH569293A5 (en:Method)
SE356146B (en:Method)
CH570269A5 (en:Method)
CH583756A5 (en:Method)
CH586060A5 (en:Method)
CH569366A5 (en:Method)
CH571664A5 (en:Method)
CH569946A5 (en:Method)
CH565732A5 (en:Method)
AU4608770A (en:Method)

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed